Skip to main content

Advertisement

SpringerLink
Log in

Pamidronate in a girl with chronic renal insufficiency dependent on parenteral nutrition

  • Brief Report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

A 10-year-old 40-kg African-American female with megacystis microcolon hypoperistalsis syndrome maintained on total parenteral nutrition (TPN), with a history of metabolic bone disease and renal insufficiency, was admitted with a Candida parapsilosis central venous line infection. During her 280-day hospital stay, she had multiple episodes of bacteremia and recurrent candidemia. Furthermore, she developed pathological fractures and hip displacement with osteomyelitis due to Enterobacter. Hypercalcemia and a history of nephrocalcinosis had prevented appropriate dosing of calcium prior to and during the first months of her hospital stay. Pamidronate and chlorothiazide were added to her regimen. The urinary calcium to creatinine ratio and ionized calcium decreased. The pamidronate dose was increased to 60 mg once a week and was well tolerated. Daily calcium was added to her TPN solution and was increased to 10 mEq/day by the time of discharge. We conclude that relatively large doses of pamidronate may be required in certain cases of refractory hypercalcemia and are well tolerated in children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.

References

  1. Srikanth MS, Ford EG, Isaacs H Jr, Mahour GH (1993) Megacystis microcolon intestinal hypoperistalsis syndrome: late sequelae and possible pathogenesis. J Pediatr Surg 28:957–959

    CAS  PubMed  Google Scholar 

  2. Koo WWK (1992) Parenteral nutrition-related bone disease. J Parenter Enter Nutr 16:386–394

    CAS  Google Scholar 

  3. Committee on Nutrition (1996) Aluminum toxicity in infants and children. Pediatrics 97:413–416

    PubMed  Google Scholar 

  4. Fleisch H (1991) Biphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919–944

    CAS  PubMed  Google Scholar 

  5. Kantrowitz FG, Byrne MH, Schiller AL, Krane SM (1975) Clinical and biochemical effects of diphosphonate in Paget's disease of bone (abstract). Arthritis Rheum 18:407

    Google Scholar 

  6. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelan F (1983) Renal failure associated with intravenous diphosphonate. Lancet 1:471

    CAS  Google Scholar 

  7. Tyrrell CJ, Collinson M, Madsen EL, Ford JM, Coleman T (1994) Intravenous pamidronate: infusion rate and safety. Ann Oncol 5 [Suppl 7]:S27–S29

  8. Astrom E, Soderhall S (1998) Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 87:64–68

    Article  CAS  PubMed  Google Scholar 

  9. Bembi B, Agosti E, Boehm P, Nassimbeni G, Zanatta M, Vidoni L (1994) Aminohydroxypropylidene-biphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3. Acta Paediatr 83:122–124

    CAS  PubMed  Google Scholar 

  10. Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G (1997) Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 131:662–665

    Google Scholar 

  11. Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A (1998) Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr 157:261–262

    CAS  Google Scholar 

  12. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952

    Google Scholar 

  13. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J (2001) Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediat Endocrinol Metab 15:529–533

    Google Scholar 

  14. Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, De Sanctis C (2000) Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 89:188–193

    Article  CAS  PubMed  Google Scholar 

  15. Sellers E, Sharma A, Rodd C (1998) The use of pamidronate in three children with renal disease. Pediatr Nephrol 12:778–781

    Article  CAS  PubMed  Google Scholar 

  16. Shaw NJ, Boivin CM, Crabtree NJ (2000) Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 83:143–145

    Article  CAS  PubMed  Google Scholar 

  17. Zacharin M, Cundy T (2000) Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates J Pediatr 137:410–415

    Google Scholar 

  18. Zacharin M, O'Sullivan M (2000) Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr 137:403–409

    Article  CAS  PubMed  Google Scholar 

  19. Brumsen C, Hamdy NAT, Papapoulos SE (1997) Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:266–283

    Google Scholar 

  20. Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT (1985) Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet II:907–910

    Google Scholar 

  21. Chakravarty K, Merry P, Scott DGI (1994) A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone. J Rheumatol 21:2118–2121

    CAS  PubMed  Google Scholar 

  22. Boudailliez BR, Pautard BJ, Sebert JL, Kremp O, Piussan CX (1990) Leukaemia-associated hypercalcemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate. Pediatr Nephrol 4:510–511

    CAS  PubMed  Google Scholar 

  23. De Schepper J, Pont S de, Smitz J, De Coster D, Schots R, Otten J (1999) Metabolic disturbances after a single dose of 30 mg pamidronate for leukaemia-associated hypercalcemia in a 11-year-old boy. Eur J Pediatr 158:765–768

    Article  PubMed  Google Scholar 

  24. Kutluk MT, Hazar V, Akyuz C, Varan A, Buyukpamukcu M (1997) Childhood cancer and hypercalcemia: report of a case treated with pamidronate. J Pediatr 130:828–831

    CAS  PubMed  Google Scholar 

  25. Lteif AN, Zimmerman D (1998) Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics 102:990–993

    CAS  PubMed  Google Scholar 

  26. Profumo RJ, Reese JC, Foy TM, Garibaldi LR, Kane RE (1994) Severe immobilization-induced hypercalcemia in a child after liver transplantation successfully treated with pamidronate. Transplantation 57:301–303

    CAS  PubMed  Google Scholar 

  27. Hoekman K, Papapoulos SE, Peters ACB, Bijvoet OLM (1985) Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 61:952–956

    CAS  PubMed  Google Scholar 

  28. Attard TM, Dhawan A, Kaufman SS, Collier DS, Langnas AN (1998) Use of disodium pamidronate in children with hypercalcemia awaiting liver transplantation. Pediatr Transplant 2:157–159

    CAS  PubMed  Google Scholar 

  29. Kodama H, Kubota K, Abe T (1998) Osteogenesis imperfecta: are fractures and growth hormone treatment linked (letter)? J Pediatr 132:559–560

    Google Scholar 

  30. Roldan EJA, Pasqualini T, Plantalech L (1999) Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients. J Pediatr Endocrinol Metab 12:555–559

    CAS  PubMed  Google Scholar 

  31. Zumkeller W, Jassoy A, Lebek S, Nagel M (2001) Clinical, endocrinological and radiological features in a child with McCune-Albright syndrome and pituitary adenoma. J Pediatr Endocrinol Metab 14:553–559

    CAS  PubMed  Google Scholar 

  32. Shaw NJ, White CP, Fraser WB, Rosenbloom L (1994) Osteopenia in cerebral palsy. Arch Dis Child 71:235–238

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, The Center for Pediatric Pharmacokinetics and Therapeutics, Pediatric Pharmacology Research Unit, University of Tennessee Health Science Center and Le Bonheur Children's Medical Center, Memphis, Tennessee, USA

    Janet L. Duke & Emily B. Hak

  2. Department of Pediatrics, The Center for Pediatric Pharmacokinetics and Therapeutics, Pediatric Pharmacology Research Unit, University of Tennessee Health Science Center and Le Bonheur Children's Medical Center, Memphis, Tennessee, USA

    Deborah P. Jones, Noel K. Frizzell, Russell W. Chesney & Emily B. Hak

  3. Department of Pharmacy, University of Tennessee Health Science Center, 26 South Dunlap, Room 515, Memphis, TN 38163, USA

    Emily B. Hak

Authors
  1. Janet L. Duke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deborah P. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noel K. Frizzell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Russell W. Chesney
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Emily B. Hak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emily B. Hak.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duke, J.L., Jones, D.P., Frizzell, N.K. et al. Pamidronate in a girl with chronic renal insufficiency dependent on parenteral nutrition. Pediatr Nephrol 18, 714–717 (2003). https://doi.org/10.1007/s00467-003-1162-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-003-1162-9

Keywords

Search

Navigation